NSTG NanoString Technologies

NanoString Announces New Products to Advance COVID-19 Disease Research

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the availability of new solutions to study the immune response in COVID-19 disease research. As part of an expanding portfolio of infectious disease research solutions, the nCounter® Host Response Gene Expression Panel and COVID -19 Panel Plus spike-in provide a comprehensive analysis of the viral infection and immune response. New protein and RNA content available on the GeoMx® Digital Spatial Profiler enable high-plex analysis of key biological pathways mapped to specific regions within infected tissues. Data to be presented at an upcoming LabRoots Coronavirus Virtual Conference on Wednesday, June 17 will demonstrate the application of these new tools in SARS-CoV-2 formalin-fixed paraffin-embedded (FFPE) tissue samples to better understand the processes underlying infection, pathogenesis and therapeutic response.

Rapid and reproducible spatial analysis of clinically relevant tissue samples is challenging due to the fixation processes required to prevent disease transmission and represents a current unmet need in the market. The COVID-19 GeoMx-formatted Antibody Panel, from Abcam, provides a customizable panel which will be run with the GeoMx Immune Profiling Core to enable spatial analysis of 96 proteins involved in the immune response to SARS-CoV-2 infection. The product was developed to provide optimal results from challenging FFPE tissue samples and is currently available through the .

The GeoMx COVID-19 Immune Response Atlas profiles spatial analysis of over 1,800 genes including receptor, protease, and viral markers associated with COVID-19 disease as well as a broad array of immune markers. Using RNAscope® probes, from Advanced Cell Diagnostics, alongside the GeoMx COVID-19 Immune Response Atlas for visualization, further enables the spatial analysis of cellular and molecular host responses. This product is currently in early access at several key research institutes and is expected to be available later this year.

“An increasing number of recent COVID-19 nCounter publications highlight the benefits of the rapid and reproducible results generated by NanoString’s nCounter and GeoMx platforms for studying the host response to pathogen infection,” said Joe Beechem, CSO and SVP of R&D NanoString Technologies. “The combination of these new products enables the broadest characterization of host response for either bulk or spatial studies and superior performance in clinically relevant samples such as FFPE.”

The and were designed in collaboration with global leaders in infectious disease biology and host-response. The Host Response Gene Expression Panel includes 770 genes focused on host susceptibility, interferon signaling, innate and adaptive immunity as well as other key areas of biology to characterize host response to infection. The COVID-19 Panel Plus spike-in contains probes targeting all SARS-CoV-2 genes as well as the host ACE receptor that is bound by the virus. The new Host Response Panel can be combined with the COVID-19 Panel Plus spike-in or custom content, enabling researchers to characterize the host and viral genes simultaneously.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 3,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s GeoMx® Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

For more information, please visit .

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions. RNAscope is a registered trademark of Advanced Cell Diagnostics.

EN
16/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NanoString Technologies

 PRESS RELEASE

NanoString Reports Inducement Grants Under Nasdaq Listing Rules

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on December 6, 2023, the Compensation and Human Capital Committee of NanoString’s Board of Directors approved the grant of, in the aggregate, 34,925 restricted stock units, or RSUs, as material inducements to the 10 employees entering into employment with NanoString. One-third of the R...

 PRESS RELEASE

NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Health...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, January 10, at 5:15pm ET. Interested parties can access the live webcast from the investor section of the company’s website at . The webcast replay will be available one hour after the conc...

 PRESS RELEASE

NanoString Comments on Delaware District Court Verdict

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty. “We respectfully disagree with the jury’s verdict, which we will seek to have overturned or amend...

 PRESS RELEASE

NanoString to Webcast Presentations from Upcoming Healthcare Conferenc...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. Stifel 2023 Healthcare Conference Tuesday, November 14th Tom Bailey, NanoString’s chief financial officer, and Doug Farrell, VP of Investor Relations, will participate in a fireside discussion hosted by Stifel analyst Dan Arias at 9:45am ET. Jefferies London Healthcare Conference Thursday, November 16th Tom Bailey, Nano...

 PRESS RELEASE

NanoString Technologies Releases Operating Results for Third Quarter o...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. “The last few months have been extraordinarily productive for our team. During the third quarter, we delivered record revenue whi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch